New pill CT-996 tested for obesity and diabetes – early results promising?

NCT ID NCT05814107

Completed Disease control Sponsor: Carmot Australia First Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a new drug called CT-996 in 94 overweight or obese adults, including some with type 2 diabetes. The main goal was to check safety and how the body processes the drug. Researchers gave single or multiple doses and monitored side effects. This is a first step to see if the drug might help with weight and blood sugar, but much more research is needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT-996 (a drug capsule)
What this could lead to: If successful, this could point toward a new oral medication for weight management and blood sugar control in type 2 diabetes.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work as hoped or could have side effects. Results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY TYPE 2 DIABETES

Contacts and locations

Locations

Avant Santé Research Center S.A. de C.V.

San Pedro Garza García, 66260, Mexico
Nucleus Network Pty Ltd.

Melbourne, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.